ClinicalTrials.gg
RecruitingNCT05204212LAA-KIDNEYUpdated May 13, 2024

Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease

An interventional study of Left Atrial Appendage closure in Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent, sponsored by Prof. Dr. med. Ingo Eitel. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Prof. Dr. med. Ingo Eitel · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 417 studies in Atrial Fibrillation with a site in Germany — 60 open to participants now, 88 under way, 4 of them phase 3. Atrial Fibrillation · Germany.

Planned enrollment
84th of 284
430 · median 200
Started
2022
with 15 others
No phase
166 of 417
31 open now
Primary completion
2026-01
later than 15 of 87 live
Registered
327th of 417
by date

Among the 417 studies in Atrial Fibrillation with a site in Germany, this one is the 84th largest by planned enrollment of the 284 interventional ones that give a count, is one of 16 that started in 2022, is one of 166 with no phase, reaches primary completion later than 15 of the 87 other live ones, and was the 327th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

60 of the 417 studies in Atrial Fibrillation with a site in Germany are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 417 studies in Atrial Fibrillation with a site in Germany, or all of them as a file.
02

Study summary

In the proposed event driven trial, LAA closure devices will be compared in a 1:1 randomization to best medical care in AF patients at high risk of stroke and bleeding with ESKD. The trial will allow the use of the CE marked and clinically used LAA device Amplatzer Cardiac Plug and/or Amulet and all approved medical therapies in AF patients with ESKD including vitamin-K antagonists (VKA), NOACs as well as antiplatelet agents or no anticoagulation in excessive bleeding risk.

Read the detailed description

The purpose of the current study is to evaluate the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) and end-stage renal failure.

03

Conditions studied

  • Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Ability to give
  • Documented NVAF (paroxysmal, persistent, or permanent)
  • CHA2DS2VASc risk score ≥2
  • Chronic kidney disease KDOQI stage 5 ( \<15 ml/min/1.73m2) with or without hemodialysis

Exclusion criteria

Exclusion Criteria:

  • Absolute to aspirin and/or clopidogrel
  • Comorbidities other than AF requiring chronic (N)OAC therapy e.g. mechanical heart valve prosthesis
  • Present LAA thrombus
  • Mobile aortic atheroma
  • Age ≤18 years
  • Patients presenting with pregnancy
  • Patients without
  • Participation in another trial
  • Expected \<2 years
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    Experimental intervention

    Percutaneous closure of the LAA by use of the CE-mark approved LAA exclusion device Amplatzer Cardiac Plug or Amulet followed by dual antiplatelet therapy with aspirin 100mg od and clopidogrel 75 mg od for 3 months. In patients with excessive bleeding risk DAPT duration can be shortened according to the physicians' discretion to a minimum of 6 weeks. Oral anticoagulants are not prescribed in this group.

    Other: Left Atrial Appendage closure

  • No intervention
    Control intervention

    No catheter-based LAA closure. Treatment with best medical care (warfarin or NOAC therapy or other best medical care if (N)OAC therapy is contraindicated).

Interventions

  • OtherLeft Atrial Appendage closure

    Percutaneous closure of the LAA

06

What researchers measure

Primary outcomes

  1. "Net clinical benefit"

    "Net clinical benefit", defined as, time to first stroke (including ischemic or hemorrhagic strokes), systemic embolism, cardiovascular or unexplained death or major bleeding (BARC 3-5)

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
  • Universität zu Lübeck
    Lübeck, Schleswig-Holstein 23538, Germany
    Recruiting
    • Ingo Eitel, Prof. Dr. med. · Contact
    • Thomas Stiermaier, Dr.med · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jan 2026, 45 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 45 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2022
First posted
Jan 24, 2022
StartActual
Mar 28, 2022
Primary completionEst.
Jan 14, 2026
CompletionEst.
Jan 14, 2028
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05204212
Lead sponsor
Prof. Dr. med. Ingo Eitel
Responsible party
Prof. Dr. med. Ingo Eitel (Director, University of Luebeck) — Sponsor-investigator
First posted
Jan 24, 2022
Start date
Mar 28, 2022
Primary completion
Jan 14, 2026 (estimated)
Completion
Jan 14, 2028 (estimated)
Last update
May 13, 2024

Study contacts

Ingo Eitel, MD
Contact
ingo.eitel@uksh.de
+49 451 500 44501
Thomas Stiermaier, MD
Contact
thomas.stiermaier@uksh.de
+49 451 500 44501

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion